Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

Two of the top technology headlines this past month was the FDA clearance of the Abbott Portico transcatheter aortic valve replacement (TAVR) device, and the first women to receive a Carmat artificial heart.

Feature | BY Dave Fornell, DAIC Editor

October 6, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

October 06, 2021

SimpleSense is an FDA cleared remote diagnostic platform. The cloth-based nanosensor technology undergarment monitors multiple patient vitals such as heart rate, blood pressure, respiration rate, and physical activity.

News | Cardiac Diagnostics

FDA Clears Nanowear Platform to Implement AI-based Home Diagnostics and Monitoring Network

October 4, 2021 – Nanowear, a hospital-at-home and remote diagnostic platform that used proprietary wearable cloth ...

October 04, 2021

The Abbott Amplatzer Talisman PFO Occlusion System is designed to treat people with a patent foramen ovale (PFO). The small opening between the upper chambers of the heart can increase the risk of recurrent ischemic stroke.

News | Structural Heart Occluders

FDA Clears Abbott Amplatzer Talisman PFO Occluder

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

October 04, 2021

Videos | Stem Cell Therapies

VIDEO: Engineered Heart Tissue Aids Research With a Heart in a Dish System

Mechanical engineering Professor Nathan Sniadecki, associate chair for research and infrastructure, mechanical ...

October 04, 2021

$A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line at the European Society of Cardiology (ESC) 2021 Congress, and was published in the New England Journal of Medicine. Data from the EMPEROR-Preserved and in EMPEROR-Reduced trials.$

News | Heart Failure

Empagliflozin Benefits Heart Failure Patients With Reduced and Preserved Ejection Fraction

October 1, 2021 — A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in ...

October 04, 2021

Videos | Structural Heart

VIDEO: Roles of the Melody and Harmony Transcatheter Pulmonary Valves in Congenital Heart Disease

Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, and principle investigator of the Medtronic ...

September 28, 2021

CardioMEMS is a wireless, battery-free sensor that is implanted into the pulmonary artery via a right heart catheterization procedure to transmit pulmonary artery pressures.

News | Heart Failure

GUIDE-HF Trial Shows Hemodynamic Guided Management Benefits Larger Heart Failure Population

September 28, 2021 — Hemodynamic guided management using the CardioMEMS device may reduce heart failure hospitalizations ...

September 28, 2021

Illustration of the Watchman transcatheter left atrial appendage (LAA) occluder being deployed into the LAA. FDA is concerned about higher rates of LAA occlusion complications in women compared to men, prompting the FDA to send a letter to providers warning them on possible poor outcomes.

Feature | Left Atrial Appendage (LAA) Occluders

FDA Concerned About Higher Rates of LAA Occlusion Complications in Women

September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly ...

September 27, 2021

Test selection should be a shared decision between patient and physician rather than directed by insurers’ test substitution policies, according to a statement published online in the Journal of the American College of Cardiology.[1] The statement summarizes the proceedings of a recent summit convened by the American Society of Nuclear Cardiology (ASNC), leadership of the American College of Cardiology Imaging Council, American Society of Echocardiography (ASE), Society of Cardiovascular Computed Tomography

News | Cardiac Imaging

Cardiovascular Imaging Organizations Denounce Test Substitution by Insurance Companies

September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by ...

September 22, 2021

Cardiothoracic surgeons with UofL Health – Jewish Hospital and the University of Louisville performed the world’s first Carmat Aeson bioprosthetic total artificial heart implantation in a female patient on Sept. 14, 2021. The device was small enough to fit into the woman's smaller chest cavity. The device is being tested as a bridge to heart transplant rather than use of a LVAD. Photo by UofL Health.

News | Heart Failure

First Woman in World Receives New Type of Artificial Heart

September 22, 2021 — A cardiothoracic surgical team with University of Louisville Health – Jewish Hospital has performed ...

September 22, 2021

News | Heart Failure

ESC Releases Guidelines on Heart Failure Management

September 21, 2021 — The European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and ...

September 21, 2021

$Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device with Shield Technology, which are transcatheter devices used to seal brain aneurysms. The company said there is a risk of the delivery system’s wire and tubes fracturing and breaking off when the system is being used to place, retrieve, or move the stent inside a patient.$

News | Cath Lab

Medtronic Recalls Neurovascular Pipeline Flex Embolization Devices for Risk of Fractures During Placement, Retrieval or Movement of Device

September 21, 2021 — Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device ...

September 21, 2021

Videos | Structural Heart

VIDEO: Abbott Structural Heart Technology Advances in 2021

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, explains the latest advances in Abbott ...

September 20, 2021

The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Feature | Structural Heart Occluders | By Dave Fornell, Editor

FDA Clears Abbott Portico TAVR System to Treat Aortic Valve Disease

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

September 20, 2021

Videos | Congenital Heart

VIDEO: The Heart Team Approach in Congenital Structural Heart Interventions

Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, explains the importance of the heart team ...

September 15, 2021